---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-050346"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:22:44.358882+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA grants Fast Track Designation to Lipocine for LPCN 1148 in decompensated cirrhosis sarcopenia

## Summary
- FDA Fast Track Designation granted to LPCN 1148 for sarcopenia in decompensated cirrhosis, an unmet medical need.
- LPCN 1148 is an oral prodrug of bioidentical testosterone; POC Phase 2 study showed improved sarcopenia and clinical outcomes.
- Fast Track benefits include more frequent FDA meetings, eligibility for Accelerated Approval, Priority Review, and Rolling Review.
- Over 382,000 U.S. patients with decompensated cirrhosis; no FDA-approved treatments for associated sarcopenia.

## SEC filing metadata
- accession: 0001493152-24-050346
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315224050346/0001493152-24-050346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315224050346/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-050346
- JSON: https://secwatch.observer/filing/0001493152-24-050346.json
- Plain text: https://secwatch.observer/filing/0001493152-24-050346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.